168 related articles for article (PubMed ID: 36564903)
1. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo.
Hwang JR; Driscoll MS
Ann Pharmacother; 2023 Aug; 57(8):948-955. PubMed ID: 36564903
[TBL] [Abstract][Full Text] [Related]
2. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
Rosmarin D; Passeron T; Pandya AG; Grimes P; Harris JE; Desai SR; Lebwohl M; Ruer-Mulard M; Seneschal J; Wolkerstorfer A; Kornacki D; Sun K; Butler K; Ezzedine K;
N Engl J Med; 2022 Oct; 387(16):1445-1455. PubMed ID: 36260792
[TBL] [Abstract][Full Text] [Related]
3. A Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo.
Grossmann MC; Haidari W; Feldman SR
J Drugs Dermatol; 2023 Jul; 22(7):664-667. PubMed ID: 37410047
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
Kang C
Drugs; 2024 May; 84(5):579-586. PubMed ID: 38625661
[TBL] [Abstract][Full Text] [Related]
7. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.
Rothstein B; Joshipura D; Saraiya A; Abdat R; Ashkar H; Turkowski Y; Sheth V; Huang V; Au SC; Kachuk C; Dumont N; Gottlieb AB; Rosmarin D
J Am Acad Dermatol; 2017 Jun; 76(6):1054-1060.e1. PubMed ID: 28390737
[TBL] [Abstract][Full Text] [Related]
8. Topical ruxolitinib: A new treatment for vitiligo.
Tavoletti G; Avallone G; Conforti C; Roccuzzo G; Maronese CA; Mattioli MA; Quaglino P; Zalaudek I; Marzano AV; Ribero S; Alberti-Violetti S
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2222-2230. PubMed ID: 37147856
[TBL] [Abstract][Full Text] [Related]
9. Implementation of the vitiligo area scoring index in clinical studies of patients with vitiligo: a scoping review.
Ceresnie MS; Warbasse E; Gonzalez S; Pourang A; Hamzavi IH
Arch Dermatol Res; 2023 Oct; 315(8):2233-2259. PubMed ID: 37029284
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
[TBL] [Abstract][Full Text] [Related]
11. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial.
Szczurko O; Shear N; Taddio A; Boon H
BMC Complement Altern Med; 2011 Mar; 11():21. PubMed ID: 21406109
[TBL] [Abstract][Full Text] [Related]
12. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
Niezgoda A; Winnicki A; Kosmalski T; Kowaliszyn B; Krysiński J; Czajkowski R
Trials; 2019 Jan; 20(1):78. PubMed ID: 30683146
[TBL] [Abstract][Full Text] [Related]
13. Assessing effectiveness of adding niosomal atorvastatin 1% ointment to topical calcineurin inhibitor treatment in non-segmental vitiligo.
Zartab H; Aflatoonian M; Shamsi-Meymandi S; Pardakhty A; Isazadeh A; Firooz A; Amiri R
J Cosmet Dermatol; 2024 Jun; 23(6):2103-2108. PubMed ID: 38348697
[TBL] [Abstract][Full Text] [Related]
14. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of topical tacrolimus 0.03% monotherapy in the treatment of non-segmental vitiligo: a randomized, controlled trial.
Saleh R; Ahmed AA; M Abd-Elmagid W
J Cosmet Dermatol; 2021 Dec; 20(12):3943-3952. PubMed ID: 33657259
[TBL] [Abstract][Full Text] [Related]
16. Surrounding Needling and Narrowband Ultraviolet B Phototherapy Treatment: Synergistic Effects for Repigmentation in Chronic, Stable Nonsegmental Vitiligo.
Chu GY; Weng SM; Huang CC; Liang WC; Hsu CH
Altern Ther Health Med; 2023 Jan; 29(1):96-103. PubMed ID: 35212646
[TBL] [Abstract][Full Text] [Related]
17. Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI).
Kitchen H; Wyrwich KW; Carmichael C; Deal LS; Lukic T; Al-Zubeidi T; Marshall C; Pegram H; Hamzavi IH; King B
Dermatol Ther (Heidelb); 2022 Jul; 12(7):1623-1637. PubMed ID: 35773559
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib cream (Opzelura) for nonsegmental vitiligo.
Med Lett Drugs Ther; 2022 Oct; 64(1660):158-159. PubMed ID: 36206166
[No Abstract] [Full Text] [Related]
19. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study.
Majid I
Photodermatol Photoimmunol Photomed; 2010 Oct; 26(5):230-4. PubMed ID: 20831696
[TBL] [Abstract][Full Text] [Related]
20. Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients.
Renert-Yuval Y; Ezzedine K; Grimes P; Rosmarin D; Eichenfield LF; Castelo-Soccio L; Huang V; Desai SR; Walsh S; Silverberg JI; Paller AS; Rodrigues M; Weingarten M; Narla S; Gardner J; Siegel M; Ibad S; Silverberg NB
JAMA Dermatol; 2024 Apr; 160(4):453-461. PubMed ID: 38477910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
